FOLLOWUS
Blood stasis syndrome of coronary heart disease: A perspective of modern medicine
Blood stasis syndrome of coronary heart disease: A perspective of modern medicine
- 中国结合医学杂志（英文版） 2014年20卷第4期 页码：300-306
- Affiliations：
Department of Cardiology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences,Beijing,China
- Author bio：
- Funds：Supported by the National Natural Science Foundation of China (No. 81173116)
DOI：10.1007/s11655-013-1332-3
中图分类号：纸质出版日期：2014，
网络出版日期：2013-7-27，
Scan for full text
Yu, G., Wang, J. Blood stasis syndrome of coronary heart disease: A perspective of modern medicine., Chin. J. Integr. Med. 20, 300–306 (2014). https://doi.org/10.1007/s11655-013-1332-3
Gui Yu, Jie Wang. Blood stasis syndrome of coronary heart disease: A perspective of modern medicine[J]. Chinese Journal of Integrative Medicine, 2014,20(4):300-306.
Yu, G., Wang, J. Blood stasis syndrome of coronary heart disease: A perspective of modern medicine., Chin. J. Integr. Med. 20, 300–306 (2014). https://doi.org/10.1007/s11655-013-1332-3 DOI：
Gui Yu, Jie Wang. Blood stasis syndrome of coronary heart disease: A perspective of modern medicine[J]. Chinese Journal of Integrative Medicine, 2014,20(4):300-306. DOI： 10.1007/s11655-013-1332-3.
摘要
The medical community as a whole is attempting to start preventive therapy for coronary heart disease (CHD) patients earlier in life. However
the main limitations of such interventions are drug resistance and adverse reactions. Additionally
traditional biomarker discovery methods for CHD focus on the behavior of individual biomarkers regardless of their relevance. These limitations have led to attempting novel approaches to multi-dimensionally investigate CHD and identify safe and efficacious therapies for preventing CHD. Recently
the benefit of Chinese medicine (CM) in CHD has been proven by increasing clinical evidence. More importantly
linking CM theory with modern biomedicine may lead to new scientific discoveries. According to CM theory
all treatments for patients should be based on patients’ syndromes. A recent epidemiological investigation has demonstrated that blood stasis syndrome (BSS) is the major syndrome type of CHD. BSS is a type of complex pathophysiological state characterized by decreased or impeded blood flow. Common clinical features of BSS include a darkish complexion
scaly dry skin
and cyanosis of the lips and nails
a purple or dark tongue with purple spots
a thready and hesitant pulse
and stabbing or pricking pain fixed in location accompanied by tenderness
mass formation and ecchymosis or petechiae. The severity of BSS is significantly correlated with the complexity of coronary lesions and the degree of stenosis
and is an important factor affecting the occurrence of restenosis after percutaneous coronary intervention. The mechanisms of BSS of CHD patients should be investigated from a modern medicine perspective. Although many studies have attempted to explore the biomedical mechanisms of BSS of CHD
from hemorheological disorders to inflammation and immune responses
the global picture of BSS of CHD is still unclear. In this article
the current status of studies investigating the biomedical mechanisms of BSS of CHD and future perspectives are discussed.
Abstract
The medical community as a whole is attempting to start preventive therapy for coronary heart disease (CHD) patients earlier in life. However
the main limitations of such interventions are drug resistance and adverse reactions. Additionally
traditional biomarker discovery methods for CHD focus on the behavior of individual biomarkers regardless of their relevance. These limitations have led to attempting novel approaches to multi-dimensionally investigate CHD and identify safe and efficacious therapies for preventing CHD. Recently
the benefit of Chinese medicine (CM) in CHD has been proven by increasing clinical evidence. More importantly
linking CM theory with modern biomedicine may lead to new scientific discoveries. According to CM theory
all treatments for patients should be based on patients’ syndromes. A recent epidemiological investigation has demonstrated that blood stasis syndrome (BSS) is the major syndrome type of CHD. BSS is a type of complex pathophysiological state characterized by decreased or impeded blood flow. Common clinical features of BSS include a darkish complexion
scaly dry skin
and cyanosis of the lips and nails
a purple or dark tongue with purple spots
a thready and hesitant pulse
and stabbing or pricking pain fixed in location accompanied by tenderness
mass formation and ecchymosis or petechiae. The severity of BSS is significantly correlated with the complexity of coronary lesions and the degree of stenosis
and is an important factor affecting the occurrence of restenosis after percutaneous coronary intervention. The mechanisms of BSS of CHD patients should be investigated from a modern medicine perspective. Although many studies have attempted to explore the biomedical mechanisms of BSS of CHD
from hemorheological disorders to inflammation and immune responses
the global picture of BSS of CHD is still unclear. In this article
the current status of studies investigating the biomedical mechanisms of BSS of CHD and future perspectives are discussed.
关键词
Blood Stasis Syndromecoronary heart diseaseModern Medicine
Keywords
Blood Stasis Syndromecoronary heart diseaseModern Medicine
references
Nabel EG, Braunwald E. A tale of coronary artery disease and myocardial infarction. N Engl J Med 2012;366:54–63.
Braunwald E. The rise of cardiovascular medicine. Eur Heart J 2012;33:838–845.
Fitzgerald R. Aspirin resistance: effect of clinical, biochemical and genetic factors. Pharmacol Ther 2011;130:213–225.
Maningat P. Needed: pragmatic clinical trials for statinintolerant patients. N Engl J Med 2011;365:2250–2251.
Azuaje F, Devaux Y, Vausort M, Yvorra C, Wagner DR. Transcriptional networks characterize ventricular dysfunction after myocardial infarction: a proof-of-concept investigation. J Biomed Inform 2010;43:812–819.
Shang QH, Xu H, Lu XY, Wen C, Shi DZ, Chen KJ. A multi-center randomized double-blind placebo-controlled trial of Xiongshao Capsule in preventing restenosis after percutaneous coronary intervention: a subgroup analysis of senile patients. Chin J Integr Med 2011;17:669–674.
He QY, Wang J, Zhang YL, Tang YL, Chu FY, Xiong XJ. Effect of Yiqi Yangyin Decoction on the quality of life of patients with unstable angina pectoris. Chin J Integr Med 2010;16:13–18.
Wang J, He QY, Zhang YL. Effect of Shenshao Tablet on the quality of life for coronary heart disease patients with stable angina pectoris. Chin J Integr Med 2009;15:328–332.
Chu FY, Wang J, Yao KW, Li ZZ. Effect of Xuefu Zhuyu Capsule on the symptoms and signs and health-related quality of life in the unstable angina patients with bloodstasis syndrome after percutaneous coronary intervention: a randomized controlled trial. Chin J Integr Med 2010;16:399–405.
Yang QY, Chen KJ, Lu S, Sun HR. Research progress on mechanism of action of Radix Astragalus in the treatment of heart failure. Chin J Integr Med 2012;18:235–240.
Xu H, Chen KJ. Integrating traditional medicine with biomedicine towards a patient-centered healthcare system. Chin J Integr Med 2011;17:83–84.
Robinson N. Integrative medicine-traditional Chinese medicine, a model? Chin J Integr Med 2011;17:21–25.
Sun XG, Wu WK, Lu ZP. Chinese integrative medicine: translation toward person-centered and balanced medicine. Chin J Integr Med 2012;18:3–6.
Li S, Zhang ZQ, Wu LJ, Zhang XG, Li YD, Wang YY. Understanding ZHENG in traditional Chinese medicine in the context of neuro-endocrine-immune network. IET Syst Biol 2007;1:51–60.
Ferreira AS, Lopes AJ. Chinese medicine pattern differentiation and its implications for clinical practice. Chin J Integr Med 2011;17:818–823.
Gao ZY, Xu H, Shi DZ, Wen C, Liu BY. Analysis on outcome of 5284 patients with coronary artery disease: the role of integrative medicine. J Ethnopharmacol 2012;141:578–583.
Xu H, Lu XY, Chen KJ. Study on correlation of bloodstasis syndrome and its accompanied syndromes with pathological changes showed in coronary angiography and restenosis after percutaneous coronary intervention. Chin J Integr Tradit West Med (Chin) 2007;27:8–13.
Wang J, Chen KJ, Weng WL, Qian ZH, Wang Y, Liu JG, et al. Study on the diagnostic criteria of blood stasis syndrome. Chin J Integr Tradit West Med (Chin) 1988;8:585–587, 589.
Angelkort B, Amann B, Lawall H. Hemorheology and hemostasis in vascular disease: a pathophysiological review. Clin Hemorheol Microcirc 2002;26:145–154.
Carallo C, Pujia A, Irace C, De Franceschi MS, Motti C, Gnasso A. Whole blood viscosity and haematocrit are associated with internal carotid atherosclerosis in men. Coron Artery Dis 1998;9:113–117.
Sweetnam PM, Thomas HF, Yarnell JW, Beswick AD, Baker IA, Elwood PC. Fibrinogen, viscosity and the 10-year incidence of ischaemic heart disease. Eur Heart J 1996;17:1814–1820.
Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG. Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke: the Edinburgh Artery Study. Circulation 2007;115:2119–2127.
Chen SS, Yang RK. Observation on the effect of treatment based on the differentiation syndrome on hemorheology of coronary heart disease patients. J Pract Integr Chin Med West Med (Chin) 1991;4:286–287.
Li JG. Observation on whole blood viscosity of 100 coronary heart disease patients with blood stasis syndrome. Chin J Convalescent Med (Chin) 2001;10:47–48.
Yi YM. Research on the hemorheology, 24 hour dynamic electrocardiograms and blood lipid of coronary heart disease patients with qi-deficiency or blood stasis syndrome. J Tradit Chin Med Hunan (Chin) 1994;10:48–49.
Lockhart CJ, Hamilton PK, Quinn CE, McVeigh GE. Endorgan dysfunction and cardiovascular outcomes: the role of the microcirculation. Clin Sci 2009;116:175–190.
Qiu RX, Luo ZQ, Yang SY, Wu SF, Zhu YY. Research on the microvascular disorders of coronary heart disease with blood stasis syndrome and dysfunction of qi result in stasis. J Tradit Chin Med (Chin) 1991;10:36–38.
Liang TJ, Gao SZ, Zhang FL, Wang T. Relationship between anti-coagulation system changes of coronary heart disease patients and different syndrome-type in traditional Chinese medicine. Chin J Integr Tradit West Med (Chin) 1995;15:599–600.
Mao YL, Yuan ZK, Huang XP, Lu FG, Tan GB, Hu ZX. The association of GMP-140, t-PA and PAI-1 levels in the plasma with the pattern of blood stasis of coronary heart disease. J Hunan Coll Tradit Chin Med (Chin) 2004;24:29–31.
Gurbel PA, Bliden KP. The stratification of platelet reactivity and activation in patients with stable coronary artery disease on aspirin therapy. Thromb Res 2003;112:9–12.
Li XF, Jiang YR, Gao ZY. Screening, identification and analysis of platelet differential functional proteins in patients with coronary heart disease of blood-stasis pattern. Chin J Integr Tradit West Med (Chin) 2010;30:467–473.
Liu Y, Yin HJ, Chen KJ. Research on the correlation between platelet gelsolin and blood-stasis syndrome of coronary heart disease. Chin J Integr Med 2011;17:587–592.
Grover-Páez F, Zavalza-Gómez AB. Endothel ial dysfunction and cardiovascular risk factors. Diabet Res Clin Pract 2009;84:1–10.
Rohatgi A, Owens AW, Khera A, Ayers CR, Banks K, Das SR, et al. Differential associations between soluble cellular adhesion molecules and atherosclerosis in the Dallas Heart Study: a distinct role for soluble endothelial cellselective adhesion molecule. Arterioscler Thromb Vasc Biol 2009;29:1684–1690.
Lin GY, Wang ZJ. Study on the Intervention of Danshen and Xiangdan injection on the endothelial injury of coronary heart disease with blood stasis syndrome patients. Tradit Chin Med Shaanxi (Chin) 2007;28:647–650.
Grundy SM. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation 2002;106:2526–2529.
Gotto AM Jr, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000;101:477–484.
Qi QG, Wang W, Bi LF, Hu LS. Discussion on the relation between blood lipid and uric acid and coronary heart disease with blood stasis syndrome patients. J Tradit Chin Med Liaoning (Chin) 2008;35:1826–1827.
Henning RJ, Sawmiller DR. Vasoactive intestinal peptide: cardiovascular effects. Cardiovasc Res 2001;49:27–37.
Huang HY, Zhu WF, Li BX. Relations of regulatory polypeptide and syndrome differentiation of traditional Chinese medicine of angina pectoris patients. Chin J Integr Tradit West Med (Chin) 1996;16:474–476.
Liu HX, Huang LJ, Jin M, Xia J, Wang YM, Wang B, et al. Research on plasma ET and NO of blood stasis and thoracic obstruction patients. Beijing J Tradit Chin Med (Chin) 1995;6:49–50.
Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women. Circulation 2003;107:391–397.
Wang Q, Huang SX, Liu JC, Zhang YK. Clinical research on the relationship between hs-CRP and the blood-stagnation pattern in coronary heart disease. Tradit Chin Med Pharm Guangxi (Chin) 2005;28:7–8.
Liu JG, Xu YG, Su QM. Study on the T cell subsets, lipid and hemorheology of coronary heart disease with blood stasis syndrome patients and their relationship. J Chin Microcirc (Chin) 1999;3:254.
0
浏览量
686
Downloads
12
CSCD
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 邮编：100091
- 联系电话：010-62886827, 62877592 传真：010-62874291
- 技术支持由北京北大方正电子有限公司提供 京ICP备05067934号-1
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
